Peter Strack

About Peter Strack

Over 25 years of oncology drug discovery experience in biotech and pharma, contributing…

Experience

1. Vice President

   Bristol Myers Squibb

   Apr 2019 — Present · Cambridge, MA, US

   Developed and continue to evolve the Radiopharmaceutical Therapy (RPT) Strategy for BMS. This has contributed to acquisition of Rayze Bio in 2024 and equity investments in Aktis and Ratio Therapeutics• Instrumental in enhancing our CELMoD protein degradation strategy via several multi-year collaborations with Evotec and BMS’s strategy for moving beyond cereblon in protein homeostasis • Collaborated with the BMS equity team to define emerging areas and strategic biotech investments e.g. Envisagenics, Exscientia, Charm, Cleave, Ikena, Repare, Light Horse, Be Bio, Metagenomi• Engage with over 25 venture capital groups yearly, including Limited Partner (LP) positions. Represent BMS at JPM investor conference.• Played a crucial role in identifying and establishing >30 multiyear collaborations supporting the development of programs from platform to asset. These efforts led to several drug approvals and numerous molecules entering the BMS pipeline- Biotech & VC collaborations include: Agios, Epizyme, Forma Therapeutics, Ikena, Northern Biologics, Adimab, Molecular Templates, Nabla Bio, Exscientia, Schrodinger, Charm, Terray, Skyhawk, Repare, Volastra, H3 Biomedicine, Envisagenics, Darwin Health, Tempus, Scenic, Evotec Proteomics 1.0 & 2.0, VantAI, A-Alpha, Synthex, Amphista, two incubators with Versant Ventures (Highline in NYC, Blueline in Toronto)- Academic collaborations: Celgene’s Recombinant Antibody Network (UCSF, Univ. of Chicago & Univ. of Toronto), Moffitt Cancer Center, Tsinghua University (China), and Celgene’s Four Cancer Consortium (Columbia, Mt. Sinai, UPenn, JHU Medical Schools)• Serve on numerous Joint Scientific Committees (JSC) working to build positive relationships with biotechs, problem solve, ensure program success and alignment with internal R & ED strategy• Sponsor for application of Large Language Models in Research at BMS• Board Observer: Ceptur (previous), Envisagenics (current)

Education

• Rutgers University

  BS

  1985 — 1989

• Rutgers University

  PhD

  1989 — 1994

Skills

• Oncology
• Enzyme Assays
• Lead Change
• Biomarkers
• Cell Biology
• Validation
• Biochemistry
• In Vitro
• Signal Transduction
• Clinical Research
• Virology
• Purification
• Protein Expression
• In Vivo
• Protein Chemistry
• Clinical Development
• Biomarker Discovery
• Assay Development
• Drug Development
• Cell
• Cancer
• Chemistry
• Drug Discovery